Skip to content
10-K

Annual Report

VIKING THERAPEUTICS, INC. VKTX

0001193125-26-046876

← back to feed
Filed
Feb 11, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Jan 31, 2026 115.55M sh
Shares Diluted FY 2025 · Dec 31, 2025 112.67M sh
Shares Diluted FY 2025 · Dec 31, 2024 109.04M sh
Shares Diluted FY 2025 · Dec 31, 2023 94.35M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$278.69M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$87.79M
Operating Cash Flow FY 2025 · Dec 31, 2023 −$73.38M
Cash And Equivalents FY 2025 · Dec 31, 2025 $165.81M
Cash And Equivalents FY 2025 · Dec 31, 2024 $26.68M
Stockholders Equity FY 2025 · Dec 31, 2025 $639.06M
Stockholders Equity FY 2025 · Dec 31, 2024 $880.28M
Current Liabilities FY 2025 · Dec 31, 2025 $76.67M
Current Liabilities FY 2025 · Dec 31, 2024 $27.41M
Total Liabilities FY 2025 · Dec 31, 2025 $76.67M
Total Liabilities FY 2025 · Dec 31, 2024 $28.04M
Current Assets FY 2025 · Dec 31, 2025 $715.6M
Current Assets FY 2025 · Dec 31, 2024 $907.22M
Total Assets FY 2025 · Dec 31, 2025 $715.73M
Total Assets FY 2025 · Dec 31, 2024 $908.32M
Eps Diluted FY 2025 · Dec 31, 2025 −$3.19
Eps Diluted FY 2025 · Dec 31, 2024 −$1.01
Eps Diluted FY 2025 · Dec 31, 2023 −$0.91
Eps Basic FY 2025 · Dec 31, 2025 −$3.19
Eps Basic FY 2025 · Dec 31, 2024 −$1.01
Eps Basic FY 2025 · Dec 31, 2023 −$0.91
Sga Expense FY 2025 · Dec 31, 2025 $48.39M
Sga Expense FY 2025 · Dec 31, 2024 $49.28M
Sga Expense FY 2025 · Dec 31, 2023 $37.02M
Rd Expense FY 2025 · Dec 31, 2025 $344.96M
Rd Expense FY 2025 · Dec 31, 2024 $101.64M
Rd Expense FY 2025 · Dec 31, 2023 $63.81M
Net Income FY 2025 · Dec 31, 2025 −$359.64M
Net Income FY 2025 · Dec 31, 2024 −$109.96M
Net Income FY 2025 · Dec 31, 2023 −$85.9M
Operating Income FY 2025 · Dec 31, 2025 −$393.34M
Operating Income FY 2025 · Dec 31, 2024 −$150.92M
Operating Income FY 2025 · Dec 31, 2023 −$100.83M
Revenue FY 2025 · Dec 31, 2025 $0
Revenue FY 2025 · Dec 31, 2024 $0
Revenue FY 2025 · Dec 31, 2023 $0